Concepedia

Heather Hinton

HH

Statistics

Publications

29

Citations

2.4K

H-Index

21

Active since

1999

Affiliations

Roche (Switzerland)(Current)

University of Dundee

Roche (United Kingdom)

Vall d'Hebron Hospital Universitari

Vall d'Hebron Institute of Oncology

Heather Hinton is an author at Roche (Switzerland) specializing in life sciences, immunology, and signal transduction.

ORCID

Publications per year

1999–2024

29

Publications

29

Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines

Christian Klein, Inja Waldhauer, Valeria Nicolini et al. · OncoImmunology · 2017 · 283 citations · Full text

, , +17

TLR9 Signaling in B Cells Determines Class Switch Recombination to IgG2a

Andrea Jegerlehner, Patrik Maurer, Juliana Bessa et al. · The Journal of Immunology · 2007 · 275 citations · Full text

, , +17

CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies

Marina Bacac, Sara Colombetti, Sylvia Herter et al. · Clinical Cancer Research · 2018 · 238 citations

, , +17

Generation and Characterization of p38β (MAPK11) Gene-Targeted Mice

Victoria A. Beardmore, Heather Hinton, Christina Eftychi et al. · Molecular and Cellular Biology · 2005 · 237 citations · Full text

, , +15

A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease

Laurence B. Peterson, Sarah Howlett, Marcin Ł. Pękalski et al. · Journal of Autoimmunity · 2018 · 150 citations · Full text

, , +16

1–5 of 29